IAbstract: Introduction: LUM-201 (ibutamoren, formerly MK-0677) is an orally administered GH secretagogue receptor agonist under development for treatment of paediatric growth hormone deficiency (PGHD) Methods: The GH Response to a single dose of LUM-201 and to other GH secretagogues used for diagnosis of PGHD were compared in 68 pediatric subjects participating in a trial for growth hormone deficiency Results: LUM-201 elicited greater GH responses than observed in GHD diagnostic tests with arginine, glucagon, clonidine, L-dopa and insulin induced hypoglycemia (median and interquartile ranges 15.0 ng/mL (3.5, 49) versus 5.5 ng/mL (1.8, 7.6) (p < 0.0001). The difference between responses was greatest in subjects with higher baseline IGF-I concentrations and higher GH responses to standard GH stimuli. Conclusion: LUM-201 elicits greater GH responses than standard stimuli in subjects with higher peak GH in response to conventional testing. and is potentially an orally administered treatment alternative to injectable rhGH in a subset of patients with adequate responses to an acute dose of LUM-201


中文翻译：

---

在儿童 GH 缺乏试验的受试者中，GH 促分泌素受体激动剂 (LUM-201) 比标准 GH 促分泌素引起更大的 GH 反应

LUM-201 在响应常规测试的具有较高峰值 GH 的受试者中引发比标准刺激更大的 GH 反应。在对急性剂量的 LUM-201 有充分反应的部分患者中，它可能是可替代注射 rhGH 的口服治疗